This e-learning course discusses the diagnostic approaches and treatments for patients with NTRK fusion positive cancer
Three different topics are covered, addressing current and future diagnostic and treatment approaches:
- Treating NTRK fusion cancer today and in the future
- Testing methodologies and tumour-specific algorithms
- Adverse events associated with TRK inhibitors
This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).
This e-learning course discusses the therapeutic role of PARP inhibitors in prostate cancer.
Key topics include:
- PARP inhibitor mechanism of action
- Prevalence of DDR mutations in prostate cancer, and somatic and germline testing
- Recent clinical trial data and ongoing studies
- Efficacy and safety profiles of PARP inhibitors
- Combination therapies and strategies for overcoming resistance
This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).
DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies not yet widely known by healthcare professionals working in oncology. This accredited e-learning covers the role of PARP inhibitors in clinical practice, at present and in the near future.
Upon completion of this e-learning you will understand why, where and how PARP inhibitors work in clinical practice, providing you with tools you can apply in your daily practice. It is designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible care.
